An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Bicycle Therapeutics (NASDAQ:BCYC) will participate in investor conferences in November, including TD Cowen 7th Annual Fall Oncology Innovation Summit on November 3rd and Jefferies London Healthcare Conference on November 15th. Live webcasts of the fireside chats will be accessible on Bicycle's website.
Positive
None.
Negative
None.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in November:
TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023; fireside chat at 10:00 a.m. ET
Jefferies London Healthcare Conference on Wednesday, November 15, 2023; fireside chat at 11:00 a.m. ET
Live webcasts of the fireside chats will be accessible in the Investors section of Bicycle’s website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available following the fireside chat dates.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. The company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC™) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase 1/2 trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase 1/2a clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.
What conferences will Bicycle Therapeutics participate in November?
Bicycle Therapeutics will participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit on November 3rd and the Jefferies London Healthcare Conference on November 15th.
Where can I access the webcasts of the fireside chats?
The live webcasts of the fireside chats will be accessible in the Investors section of Bicycle's website at www.bicycletherapeutics.com.
Will there be replays of the webcasts available?
Archived replays of the webcasts will be available following the fireside chat dates.
Bicycle Therapeutics plc American Depositary Shares
bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun
